Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program

OBJECTIVE: Tofacitinib is an oral JAK inhibitor indicated for the treatment of rheumatoid arthritis (RA). We characterized lymphoma events in the tofacitinib RA clinical development program. METHODS: Lymphoma events (up to March 2015) were identified from 19 tofacitinib studies (2 phase I, 9 phase I...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Arthritis Care Res (Hoboken)
Huvudupphovsmän: Mariette, Xavier, Chen, Connie, Biswas, Pinaki, Kwok, Kenneth, Boy, Mary G.
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2018
Ämnen:
Rheumatoid Arthritis
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5947561/
https://ncbi.nlm.nih.gov/pubmed/28941219
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acr.23421
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk